Borg Rikke, Carlson Nicholas, Søndergaard Jens, Persson Frederik
Department of Nephrology, Zealand University Hospital Roskilde, Roskilde, Denmark.
Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Int J Nephrol. 2023 Mar 1;2023:9609266. doi: 10.1155/2023/9609266. eCollection 2023.
Chronic kidney disease (CKD) is becoming one of the world's most prevalent noncommunicable chronic diseases. The World Health Organization projects CKD to become the 5th most common chronic disease in 2040. Causes of CKD are multifactorial and diverse, but early-stage symptoms are often few and silent. Progression rates are highly variable, but patients encounter both an increased risk for end-stage kidney disease (ESKD) as well as increased cardiovascular risk. End-stage kidney disease incidence is generally low, but every single case carries a significant burden of illness and healthcare costs, making prevention by early intervention both desirable and worthwhile. This review focuses on the prevalence, diagnosis, and causes of CKD. In addition, we discuss the developments in the general treatment of CKD, with particular attention to what can be initiated in general practice. With the addition of recent landmark findings and the expansion of the indication for using sodium-glucose cotransporter 2 inhibitors, there are now new effective treatments to add to standard therapy. This will also be relevant for primary care physicians as many patients with CKD have their family physician as their primary health care professional handling kidney function preservation. In the future, more precise and less invasive diagnostic methods may not only improve the determination of the underlying cause of CKD but may also carry information regarding which treatment to use (i.e. personalized medicine). This could lead to a reduced number of preventive treatments per individual, while at the same time improving the prognosis. This review summarizes ongoing efforts in this area.
慢性肾脏病(CKD)正成为全球最普遍的非传染性慢性病之一。世界卫生组织预计,到2040年CKD将成为第五大常见慢性病。CKD的病因是多因素且多样的,但早期症状往往很少且不明显。疾病进展速度差异很大,但患者面临终末期肾病(ESKD)风险增加以及心血管风险增加的问题。终末期肾病的发病率通常较低,但每一个病例都带来了巨大的疾病负担和医疗费用,因此通过早期干预进行预防既可取又有价值。本综述重点关注CKD的患病率、诊断和病因。此外,我们还讨论了CKD一般治疗的进展,特别关注在全科医疗中可以开展的治疗措施。随着近期具有里程碑意义的研究结果的出现以及钠-葡萄糖协同转运蛋白2抑制剂使用指征的扩大,现在有了可添加到标准治疗中的新的有效治疗方法。这对基层医疗医生也很重要,因为许多CKD患者的家庭医生是负责其肾功能维护的主要医疗保健专业人员。未来,更精确、侵入性更小的诊断方法不仅可能改善对CKD潜在病因的判定,还可能提供关于使用何种治疗方法(即个性化医疗)的信息。这可能导致每个人预防性治疗的数量减少,同时改善预后。本综述总结了该领域正在进行的工作。